BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 18361806)

  • 1. A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
    Jackson C; Cunningham D
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S8-15. PubMed ID: 18361806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
    Zhang W; Gordon M; Lenz HJ
    Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
    Eng C
    Oncologist; 2010; 15(1):73-84. PubMed ID: 20067946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
    J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.
    Chua YJ; Cunningham D
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S81-8. PubMed ID: 16336753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.
    Wu M; Rivkin A; Pham T
    Clin Ther; 2008 Jan; 30(1):14-30. PubMed ID: 18343240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
    Kim GP; Grothey A
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S89-97. PubMed ID: 16336754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
    Larsen FO; Markussen A; Nielsen D; Colville-Ebeling B; Riis LB; Jensen BV
    Oncology; 2017; 93(3):191-196. PubMed ID: 28531891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.
    Hecht JR
    Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S15-21; quiz S22-4. PubMed ID: 18499885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.
    Ciardiello F; Tejpar S; Papamichael D
    Target Oncol; 2009 Dec; 4(4):311-22. PubMed ID: 19915942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.